(CCJ) Cameco - Overview
Exchange: NYSE •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA13321L1085
Stock:
Total Rating 72
Risk 88
Buy Signal -0.25
| Risk 5d forecast | |
|---|---|
| Volatility | 50.0% |
| Relative Tail Risk | -5.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.03 |
| Alpha | 149.13 |
| Character TTM | |
|---|---|
| Beta | 1.389 |
| Beta Downside | 1.466 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.01% |
| CAGR/Max DD | 1.57 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 117.8515
Description: CCJ Cameco
Cameco Corporation provides uranium for the generation of electricity in the Americas, Europe, and Asia. It operates in three segments: Uranium, Fuel Services, and Westinghouse. The Uranium segment engages in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its Fuel Services segment is involved in the refining, conversion, and fabrication of uranium concentrate, as well as purchase and sale of conversion services. The Westinghouse segment operates as a nuclear reactor technology original equipment manufacturer and a provider of products and services to commercial utilities and government agencies. It also provides outage and maintenance, engineering support, instrumentation and controls equipment, and plant modification services, as well as components and parts to nuclear reactors. The company sells its uranium and fuel products and services to nuclear utilities. Cameco Corporation was incorporated in 1987 and is headquartered in Saskatoon, Canada.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 589.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.17 > 1.0 |
| NWC/Revenue: 45.04% < 20% (prev 23.52%; Δ 21.52% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.39b > Net Income 589.4m |
| Net Debt (-91.9m) to EBITDA (1.05b): -0.09 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.5m) vs 12m ago -0.21% < -2% |
| Gross Margin: 29.40% > 18% (prev 0.25%; Δ 2915 % > 0.5%) |
| Asset Turnover: 34.47% > 50% (prev 31.65%; Δ 2.81% > 0%) |
| Interest Coverage Ratio: 10.04 > 6 (EBITDA TTM 1.05b / Interest Expense TTM 74.5m) |
Altman Z'' 4.71
| A: 0.15 (Total Current Assets 2.64b - Total Current Liabilities 1.07b) / Total Assets 10.29b |
| B: 0.35 (Retained Earnings 3.61b / Total Assets 10.29b) |
| C: 0.07 (EBIT TTM 748.3m / Avg Total Assets 10.10b) |
| D: 1.97 (Book Value of Equity 6.69b / Total Liabilities 3.40b) |
| Altman-Z'' Score: 4.71 = AA |
Beneish M -3.16
| DSRI: 1.08 (Receivables 372.0m/309.6m, Revenue 3.48b/3.14b) |
| GMI: 0.85 (GM 29.40% / 24.96%) |
| AQI: 0.89 (AQ_t 0.42 / AQ_t-1 0.47) |
| SGI: 1.11 (Revenue 3.48b / 3.14b) |
| TATA: -0.08 (NI 589.4m - CFO 1.39b) / TA 10.29b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of CCJ shares?
As of February 27, 2026, the stock is trading at USD 118.18 with a total of 3,587,214 shares traded.
Over the past week, the price has changed by -0.71%, over one month by -2.54%, over three months by +33.33% and over the past year by +164.78%.
Over the past week, the price has changed by -0.71%, over one month by -2.54%, over three months by +33.33% and over the past year by +164.78%.
Is CCJ a buy, sell or hold?
Cameco has received a consensus analysts rating of 4.53.
Therefore, it is recommended to buy CCJ.
- StrongBuy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CCJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.4 | 6.1% |
| Analysts Target Price | 125.4 | 6.1% |
CCJ Fundamental Data Overview February 21, 2026
P/E Trailing = 117.8515
P/E Forward = 81.3008
P/S = 14.8997
P/B = 9.8449
P/EG = 3.33
Revenue TTM = 3.48b USD
EBIT TTM = 748.3m USD
EBITDA TTM = 1.05b USD
Long Term Debt = 996.3m USD (from longTermDebt, last quarter)
Short Term Debt = 3.34m USD (from shortTermDebt, last quarter)
Debt = 1.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.9m USD (from netDebt column, last quarter)
Enterprise Value = 51.69b USD (51.88b + Debt 1.02b - CCE 1.21b)
Interest Coverage Ratio = 10.04 (Ebit TTM 748.3m / Interest Expense TTM 74.5m)
EV/FCF = 49.06x (Enterprise Value 51.69b / FCF TTM 1.05b)
FCF Yield = 2.04% (FCF TTM 1.05b / Enterprise Value 51.69b)
FCF Margin = 30.26% (FCF TTM 1.05b / Revenue TTM 3.48b)
Net Margin = 16.93% (Net Income TTM 589.4m / Revenue TTM 3.48b)
Gross Margin = 29.40% ((Revenue TTM 3.48b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 22.24% (prev 37.32%)
Tobins Q-Ratio = 5.02 (Enterprise Value 51.69b / Total Assets 10.29b)
Interest Expense / Debt = 1.88% (Interest Expense 19.3m / Debt 1.02b)
Taxrate = 19.22% (47.3m / 246.2m)
NOPAT = 604.5m (EBIT 748.3m * (1 - 19.22%))
Current Ratio = 2.47 (Total Current Assets 2.64b / Total Current Liabilities 1.07b)
Debt / Equity = 0.15 (Debt 1.02b / totalStockholderEquity, last quarter 6.90b)
Debt / EBITDA = -0.09 (Net Debt -91.9m / EBITDA 1.05b)
Debt / FCF = -0.09 (Net Debt -91.9m / FCF TTM 1.05b)
Total Stockholder Equity = 6.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.84% (Net Income 589.4m / Total Assets 10.29b)
RoE = 8.76% (Net Income TTM 589.4m / Total Stockholder Equity 6.73b)
RoCE = 9.69% (EBIT 748.3m / Capital Employed (Equity 6.73b + L.T.Debt 996.3m))
RoIC = 7.82% (NOPAT 604.5m / Invested Capital 7.73b)
WACC = 10.85% (E(51.88b)/V(52.90b) * Re(11.03%) + D(1.02b)/V(52.90b) * Rd(1.88%) * (1-Tc(0.19)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.15%
[DCF] Terminal Value 72.58% ; FCFF base≈872.4m ; Y1≈1.08b ; Y5≈1.83b
[DCF] Fair Price = 45.08 (EV 19.54b - Net Debt -91.9m = Equity 19.63b / Shares 435.5m; r=10.85% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 47.76 | EPS CAGR: 96.11% | SUE: 1.49 | # QB: 1
Revenue Correlation: 76.99 | Revenue CAGR: 34.21% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.36 | Chg7d=-0.072 | Chg30d=-0.104 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-12-31): EPS=1.55 | Chg7d=-0.395 | Chg30d=-0.423 | Revisions Net=-9 | Growth EPS=+7.3% | Growth Revenue=-0.5%
EPS next Year (2027-12-31): EPS=2.52 | Chg7d=-0.041 | Chg30d=-0.039 | Revisions Net=+1 | Growth EPS=+63.0% | Growth Revenue=+15.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 10.2% (Discount Rate 11.0% - Earnings Yield 0.8%)
[Growth] Growth Spread = -7.2% (Analyst 3.0% - Implied 10.2%)
P/E Forward = 81.3008
P/S = 14.8997
P/B = 9.8449
P/EG = 3.33
Revenue TTM = 3.48b USD
EBIT TTM = 748.3m USD
EBITDA TTM = 1.05b USD
Long Term Debt = 996.3m USD (from longTermDebt, last quarter)
Short Term Debt = 3.34m USD (from shortTermDebt, last quarter)
Debt = 1.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.9m USD (from netDebt column, last quarter)
Enterprise Value = 51.69b USD (51.88b + Debt 1.02b - CCE 1.21b)
Interest Coverage Ratio = 10.04 (Ebit TTM 748.3m / Interest Expense TTM 74.5m)
EV/FCF = 49.06x (Enterprise Value 51.69b / FCF TTM 1.05b)
FCF Yield = 2.04% (FCF TTM 1.05b / Enterprise Value 51.69b)
FCF Margin = 30.26% (FCF TTM 1.05b / Revenue TTM 3.48b)
Net Margin = 16.93% (Net Income TTM 589.4m / Revenue TTM 3.48b)
Gross Margin = 29.40% ((Revenue TTM 3.48b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 22.24% (prev 37.32%)
Tobins Q-Ratio = 5.02 (Enterprise Value 51.69b / Total Assets 10.29b)
Interest Expense / Debt = 1.88% (Interest Expense 19.3m / Debt 1.02b)
Taxrate = 19.22% (47.3m / 246.2m)
NOPAT = 604.5m (EBIT 748.3m * (1 - 19.22%))
Current Ratio = 2.47 (Total Current Assets 2.64b / Total Current Liabilities 1.07b)
Debt / Equity = 0.15 (Debt 1.02b / totalStockholderEquity, last quarter 6.90b)
Debt / EBITDA = -0.09 (Net Debt -91.9m / EBITDA 1.05b)
Debt / FCF = -0.09 (Net Debt -91.9m / FCF TTM 1.05b)
Total Stockholder Equity = 6.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.84% (Net Income 589.4m / Total Assets 10.29b)
RoE = 8.76% (Net Income TTM 589.4m / Total Stockholder Equity 6.73b)
RoCE = 9.69% (EBIT 748.3m / Capital Employed (Equity 6.73b + L.T.Debt 996.3m))
RoIC = 7.82% (NOPAT 604.5m / Invested Capital 7.73b)
WACC = 10.85% (E(51.88b)/V(52.90b) * Re(11.03%) + D(1.02b)/V(52.90b) * Rd(1.88%) * (1-Tc(0.19)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.15%
[DCF] Terminal Value 72.58% ; FCFF base≈872.4m ; Y1≈1.08b ; Y5≈1.83b
[DCF] Fair Price = 45.08 (EV 19.54b - Net Debt -91.9m = Equity 19.63b / Shares 435.5m; r=10.85% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 47.76 | EPS CAGR: 96.11% | SUE: 1.49 | # QB: 1
Revenue Correlation: 76.99 | Revenue CAGR: 34.21% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.36 | Chg7d=-0.072 | Chg30d=-0.104 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-12-31): EPS=1.55 | Chg7d=-0.395 | Chg30d=-0.423 | Revisions Net=-9 | Growth EPS=+7.3% | Growth Revenue=-0.5%
EPS next Year (2027-12-31): EPS=2.52 | Chg7d=-0.041 | Chg30d=-0.039 | Revisions Net=+1 | Growth EPS=+63.0% | Growth Revenue=+15.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 10.2% (Discount Rate 11.0% - Earnings Yield 0.8%)
[Growth] Growth Spread = -7.2% (Analyst 3.0% - Implied 10.2%)